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Abstract: In many instances, multidrug resistance (MDR) is mediated by increasing the expres-
sion at the cell surface of the MDR1 gene product, P-glycoprotein (P-gp), a 170-kD energy-depen-
dent efflux pump. The aim of this study was to investigate the potential benefit of combination 
therapy with magnetic Fe3O4 nanoparticle [MNP (Fe3O4)] and MDR1 shRNA expression vector 
in K562/A02 cells. For stable reversal of “classical” MDR by short hairpin RNA (shRNA) aiming 
directly at the target sequence (3491–3509, 1539–1557, and 3103–3121 nucleotide) of MDR1 
mRNA. PGC silencer-U6-neo-GFP-shRNA/MDR1 called PGY1–1, PGY1–2, and PGY1–3 
were constructed and transfected into K562/A02 cells by lipofectamine 2000. After transfected 
and incubated with or without MNP (Fe3O4) for 48 hours, the transcription of MDR1 mRNA 
and the expression of P-gp were detected by quantitative real-time PCR and Western-blot assay 
respectively. Meanwhile intracellular concentration of DNR in K562/A02 cells was detected by 
flow cytometry (FCM). PGC silencer-U6-neo-GFP-shRNA/MDR1 was successfully constructed, 
which was confirmed by sequencing and PGY1–2 had the greatest MDR1 gene inhibitory ratio. 
Analysis of the reversal ratio of MDR, the concentration of daunorubicin (DNR) and the tran-
scription of MDR1 gene and expression of P-gp in K562/A02 showed that combination of DNR 
with either MNP (Fe3O4) or PGY1–2 exerted a potent cytotoxic effect on K562/A02 cells, while 
combination of MNP (Fe3O4) and PGY1–2 could synergistically reverse multidrug resistance. Thus 
our in vitro data strongly suggested that a combination of MNP (Fe3O4) and shRNA expression 
vector might be a more sufficient and less toxic anti-MDR method on leukemia.
Keywords: K562/A02 cell line, multidrug resistance, magnetic nanoparticle of Fe3O4, 
  recombinant plasmid vector PGY1–2
Introduction
Multidrug resistance (MDR) is a well-defined phenomenon of cross-resistance of mam-
malian cells to a number of anticancer agents following exposure to one such drug. It is 
a major obstacle to successful chemotherapy in leukemia and more than 90% of patients 
with malignant tumor died of MDR.1 A diverse range of agents involved in MDR 
include alkaloid compounds, bacterial and fungal antibiotics such as anthracyclines 
and etoposide. An accepted mechanism of MDR is related to a reduced intracellular 
accumulation and the altered subcellular distribution of toxic drugs, which is   mediated 
by over expression of P-glycoprotein (P-gp) at the cell surface in many instances. P-gp, 
which is encoded by the MDR1 gene, is a major organic action transporter in tissues 
responsible for the excretion of xenobiotics (both drugs and toxins) by the biliary tract 
and proximal tubule of the kidney, so as to decrease intracellular drug accumulation. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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It is generally accepted that any access which could increase 
the effective concentration of intracellular chemotherapeutic 
agent was available to enhance the agent therapy.
In recent years, drugs packaged by liposome or multi-
mer have been developed. Nanoparticle techniques have 
been paid more close attention and nanoparticles have been 
introduced as drug delivery systems to enhance the efficiency 
of anticancer drug delivery based on the ability to target 
specific locations in the body.2 MNP (Fe3O4) described in 
our previous studies have good biocompatibility and low 
cytotoxicity,3,4 which could increase the intracellular effec-
tive concentration of chemotherapeutic drugs in vitro so as 
to reverse MDR.5,6 Some other reports have demonstrated 
that MNP (Fe3O4) has the synergistic effect with the antican-
cer drug DNR on the drug accumulation of leukemia cells 
both in vitro and in vivo.4,7,8 The diameter of MNP (Fe3O4) 
manufactured by Biological Science College of Southeast 
University is 20–30 nm.7 An understanding of the interface 
between the MNP (Fe3O4) and anticancer agents to reverse 
MDR, for their application and safety, are imperative to 
advance nanomedicine.
Another key problem for tumor treatment, as we know, 
is to reduce the sensitivity of tumor cells to cytotoxic drugs. 
Such an alternative procedure to circumvent MDR1/P-gp 
mediated MDR in cancer cells is to prevent the biosyn-
thesis of MDR1/P-gp by gene therapeutic technologies. 
RNA interference (RNAi) technology is currently used 
not only as a powerful tool for analyzing gene function, 
but also for developing highly specific therapeutics,9–11 
which relies on the sequence-specific interaction between 
small interfering RNA (siRNAs) and mRNA. Degradation 
of long double-stranded RNA to siRNA is mediated by a 
double-stranded RNA-specific RNase III Dicer. The siRNAs 
are incorporated into a nuclease complex known as RNA-
induced silencing complex (RISC), where unwinding of 
the duplex siRNAs takes place. The antisense strand binds 
in a highly sequence-specific manner to target mRNA, 
which is then endonucleolytically cleaved and degraded.7 
It has recently been shown that RNAi can be achieved in 
cultured mammalian cells using siRNAs with a length of 
21–23 bp.12 However, the half-life of P-gp (at least 16 h) 
makes it difficult to achieve a complete knock-down of 
P-gp.13 Little in vitro data is available in investigating the 
combination of MNP (Fe3O4) with siRNA for reversing 
MDR. Therefore, the effective shRNA PGY1–2, is used 
to be combined with MNP (Fe3O4) to sensitize MDR cells 
as anticancer agents in vitro, and to find a low mammalian 
  toxicity, high-efficiency and high-selectivity modulator.
Materials and methods
Main reagents
Adriamycin® (ADM; Hisun Pharmaceutical Co, Zhejiang, 
China) and daunorubicin (DNR; Main Luck Pharmaceu-
ticals Inc., Shenzhen, China) stock solution (2 mg/mL) 
were prepared with 0.01 mol/L phosphate buffer saline 
(PBS, pH7.4). Nanoparticles Fe3O4 (State Key Lab of 
Bioelectronics, Chien-Shiung Wu Laboratory, Southeast 
University, Nanjing, China) were well distributed in RPMI 
1640 medium (Gibco®/BRL, Carlsbad, CA, USA) containing 
10% (v/v) heat-inactivated new-born calf serum (Sijiqing, 
Hangzhou, China) by using ultrasound treatment in order to 
obtain MNP (Fe3O4) colloidal suspension. 1.0 µg/mL DNR 
conjugated with 10 µg/mL MNP (Fe3O4) were prepared by 
mechanical absorption polymerization at 4°C for 48 hours 
as previously.8,14 T4 DNA ligase, BamHI, Hind III NEB. 
Opti-MEM® (Gibco®). Trizol® reagent (Invitrogen Life 
Technologies, Carlsbad, CA, USA); SYBR® Green I dye 
(Takara, Shiga, Japan); Rotor-Gene 3000 (Corbett Research, 
Sydney, Australia).
Cell lines and culture conditions
Human leukemia cell line K562 and its Adriamycin®-selected 
P-gp-over expressing subline K562/A02 were obtained from 
the Institute of Hematology, Chinese Academy of Medical 
ZSciences (Tianjin, China). Both cells were cultured in 
RPMI 1640 medium (Gibco®/BRL) containing 10% (v/v) 
heat-inactivated new-born calf serum, 100 U/mL penicillin, 
and 100 µg/mL streptomycin at 37°C, 5% CO2 incubator. 
K562/A02 was cultured in the medium containing 1 µg/mL 
ADM for maintaining MDR phenotype, and maintained in 
drug-free medium for at least seven days before use. Briefly, 
cells were incubated with MNP (Fe3O4) and/or PGY1–2 at 
37°C for 48 hours.
Vector construction and identification
Three 19-nt siRNAs targeting different nucleotide sites of 
MDR1 mRNA (M14758.1) designed according to the Tuschl 
principles7 were 5'-GGCCTAATGCCGAACACAT-3' (3491–
3509 nt); 5'-GTATTGACAGCTATTC GAA-  3'(1539–1557 nt) 
and 5'-GATCGCTAC TGAAGCAATA-3'(3103–3121 nt). 
BLAST research was performed to ensure that the shRNAs 
did not have significant sequence homology with other genes. 
The 66-nt oligonucleotides were annealed and cloned into the 
BamHI and HindIII sites of the PGC   silencer-U6-neo-GFP 
vector. The shRNA expression vectors called PGY1–1, 
PGY1–2, and PGY1–3 were designated and confirmed by 
sequencing.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Transfection
The human leukemia cell line K562/A02 was transfected in 
Opti-MEM® I medium using Lipofectamine™ 2000 (Invitro-
gen) under serum-free conditions according to the manufac-
turer’s recommendations. The plasmid (µg) to Lipofectamine 
2000 (µL) was used to prepare for complexes at the ratio of 
2:5. Cells were incubated at 37°C in a 5% CO2 incubator 
for 48 hours for transgene expression. After staining with 
SYBR® Green I, the cells were calculated and differentiated 
according to whether the cell could light green fluorescence 
or not under the fluorescence microscope. The transfected 
efficiency was calculated by the ratio of transfected cells in 
one hundred of K562/A02 cells.
Cytotoxicity assay
The in vitro chemosensitivity was measured by 3-(4, 
5-  dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) (Sigma Aldrich, USA) assay. Account for the results 
of transfection and our previous reports, 1.3 µg/mL PGY1–2 
vector, and 10 µg/mL MNP (Fe3O4)7,8 were selected for our 
study. Briefly, 1.5 × 105/mL cells were suspended in 100 µL 
culture medium on 96-well culture plate (Costar; Fisher 
Scientific, Hampton, NH, USA) per well. To determine the 
antiproliferative effect of PGY1–2, MNP (Fe3O4) or DNR, a 
different concentration of DNR with or without 10 µg/mL 
MNP (Fe3O4) and 1.3 µg/mL PGY1–2 vector were added into 
100 µL dilution of the culture medium. Meanwhile, RPMI 
1640 medium was regarded as the bank control and cells 
without reagents were the negative control. After incubation 
for 48 hours at 37°C, 20 µL MTT (0.5 mg/mL) were added 
to each well and cultured for another 4 hours. The formazan 
was dissolved with 150 µL dimethyl sulfoxide (Sigma Aldrich, 
USA) after blotting the culture medium. The plates were 
shaken lightly for 10 minutes, and the reduction of MTT was 
quantified by absorbance at a wavelength of 540 nm using a 
microplate reader (Model-550; Bio-Rad Laboratories, Her-
cules, CA, USA).
Quantitative real-time PCr analysis
After treatment with drugs as described in cytotoxicity assay, 
total RNA was isolated using Trizol reagent according to the 
manufacturer’s protocol. One microgram of RNA was used to 
generate cDNA using SuperScript™ II Reverse Transcriptase 
(Invitrogen Life Technologies). Primers involved were the 
MDR1 (205 bp) primers (forwards 5'-CCATCATTGCAATA 
GCAGG-3', reverse 5'-AGGAGCAGAAGT TTGAAC-3')
and the GAPDH primers (forwards 5'-CGGATTTGGTCGTAT 
TG-3', reverse 5'-GAAGATGGTGATGGGATT-3'). QPCR 
was performed by monitoring in real-time the increase of 
fluorescence of SYBR® Green I dye with Rotor-Gene 3000 
(Corbett Research, Sydney Australia). The relative gene copy 
number was calculated by the concentration-CT standard 
curve method and normalized using the average expression 
of GAPDH.
Western blot analysis
In order to examine the expression of P-gp, Western-blot 
assay was performed to analyze the level of protein from 
cells treated for 48 hours as described previously.8 Briefly, 
total protein was isolated and subjected to 10% sodium 
dodecyl sulfate PAGE, and transferred to a polyvinylidene 
difluoride membrane (  Bio-Rad, Hercules, CA). The blots 
were stained with mouse anti-P-gp or mouse anti-β-actin 
(1:1000–1:1200) in 5% nonfat dry milk overnight at 4°C, 
and then with horseradish peroxidase conjugated goat anti-
rabbit as a secondary antibody (1:5000) for 1 hour at room 
temperature. The signal was detected with the enhanced 
chemiluminescence (ECL) Western Blotting   Detection Kit 
(Zhong Shan Co, Beijing, China). After normalization by 
the corresponding expression of β-actin, the levels of P-gp 
protein expression were determined by densitometry scans 
(ECL system, Amersham, UK).
Cellular accumulation of DNr
The intracellular concentration of DNR in K562/A02 cells 
was determined by flow cytometry (FCM) assay. Briefly, 
K562/A02 cells were treated as described in cytotoxicity 
assay, collected and then incubated with CD34-FITC for 
15 minutes. After being washed with PBS three times, cells 
were suspended and determined by a FCM (Becton Dickinson, 
USA) assay at excitation and emission wavelengths of 488 nm 
and 575 nm, respectively.
statistical analysis
All experiments were repeated at least three times, data were 
expressed as mean ± SD and analyzed with the Statistical 
Package for Social Science (SPSS Release 11.5; SPSS Inc., 
Chicago, IL, USA). Differences among various groups were 
evaluated using one-way ANOVA. A P value of 0.05 was 
considered to be statistically significant.
Results
Vector feature
According to the targeting sequences, three pairs of 66-nt 
oligonucleotides coding shRNAs containing 19-nt reverted 
repeat, 9-nt linker sequence for all hairpins, HindIII International Journal of Nanomedicine 2010:5
U6 promoter
pGCsi-U6/Neo/GFP/shRNA
6422 bp
shRNA
CMV promoter
GFP
SV40 promoter
Neomycin
pUC ori
Ampicillin
Figure 1 Construction of PgC silencer-U6-neo-gFP-shrNA expression system.
Notes: U6 Promoter: 6077–6422; shrNA: 9–55; CMV promoter: 105–704; gFP: 
709–1428; sV40 Promoter: 2098–2475; Neomycin: 2503–3297; pUC ori: 3534–4702; 
Ampicillin: 4805–5659.
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and BamHI restriction enzyme sites were designed and 
synthesized (Figure 1).
sequencing results
The shRNA expression vector called PGY1–1, PGY1–2 
and PGY1–3 were designated by sequencing. Based on the 
sequencing of PGY1–1, PGY1–2 and PGY1–3, shRNA was 
cloned into the vector successfully, respectively. (Figures 2 
A, B, C).
Transfected cell morphology
When the recombinant plasmids having GFP gene were 
transfected into K562/AO2 cells successfully, green fluo-
rescence could be observed in these cells under fluorescence 
microscope. The transfected efficiency was 19.9% ± 1.2%, 
while there were no green fluorescence observed in the cells 
of control group (P , 0.05) (Figure 3).
screening masculine clone
The transcription of MDR1 was significantly lower in K562/
A02 cells transfected with PGY1–1, PGY1–2 or PGY1–3 
than that in control group (P , 0.05). Furthermore, the 
transcription of MDR1 in K562/A02 transfected with 
PGY1–2 was less than that in transfected cells with PGY1–1 
or PGY1–3 (P , 0.05), suggesting the PGY1–2 was the 
masculine clone we wanted to choose, which was further 
demonstrated by our Western-blot assay. Lower expression 
of P-gp in K562/A02 transfected with PGY1–2 than that in 
cells transfected with PGY1–1 or PGY1–3 was detected by 
ECL system (P , 0.05) (Figure 4).
Cell growth and inhibition
The MTT assay revealed that the growth and inhibition of 
DNR, MNP (Fe3O4) with DNR, PGY1–2 with DNR, MNP 
(Fe3O4) and PGY1–2 with DNR to K562/A02 cells. MNP 
(Fe3O4) and PGY1–2 symphysially showed significant 
reversal effect on DNR resistance in K562/A02 cell line, 
and its potency was greater than using MNP (Fe3O4) and 
PGY1–2 alone. The inhibitory concentration at 50% 
(IC50) of DNR decreased from (14.82 ± 0.96) µg/mL to 
(0.97 ± 0.41) µg/mL (P , 0.05) at the combination of 
10 µg/mL MNP (Fe3O4) and 1.3 µg/mL PGY1–2 with 
DNR, while the values were down to (4.75 ± 0.59) µg/mL 
and (1.08 ± 0.37) µg/mL for MNP (Fe3O4) and PGY1–2, 
respectively (P , 0.05). The fold reversals were 15.3 of the 
synergia compared with the 3.15 of MNP (Fe3O4) and 13.7 
of PGY1–2 alone (Table 1).
Transcription of MDr1 by QPCr
To determine whether the shRNA expression vectors target-
ing MDR1 gene combined with MNP (Fe3O4) could down-
regulate gene expression, K562/A02 cells were transfected 
with PGY1–2. DNR in the absence or presence of MNP 
(Fe3O4) or vector PGY1–2 all down-regulated the transcrip-
tion of MDR1 in K562/A02 cells, these were statistically 
significant when compared to parented sensitive K562 cells 
(P , 0.05). Interestingly, MNP (Fe3O4) and PGY1–2 with 
DNR together decreased the expression of MDR1 mRNA 
more effectively than MNP (Fe3O4) or PGY1–2 with DNR, 
respectively (P , 0.05) (Figure 5), suggesting the combination 
of MNP (Fe3O4) and PGY1–2 has a potential benefit to sensitize 
MDR cells for down-regulating the transcription of MDR1.
expression of P-gp protein  
by Western-blot assay
The effect of the shRNA/MDR1 on P-gp expression was 
determined by measuring cell surface P-gp. The inhibitory 
effect of shRNA expression vector combined with MNP 
(Fe3O4) on cellular P-gp in K562/A02 cells was assayed by 
Western-blot assay (Figure 6).The expression of P-gp in 
K562/A02 cells incubated with combination of MNP (Fe3O4) 
and PGY1–2 with DNR was decreased than that with shRNA 
expression vector or MNP (Fe3O4), respectively (P , 0.05), 
suggesting that MNP (Fe3O4) and PGY1–2 together has a 
potential benefit to sensitize MDR cells down-regulating the 
expression of P-gp.International Journal of Nanomedicine 2010:5
Figure  3  Morphology  of  K562/A02  cells  after  transfected  for  48  hours  under 
fluorescence microscope (400× sYBr® green I staining).
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G
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A
B
C
Figure 2 sequence of shrNA/MDr1.
Notes: A) PgY1–1; B) PgY1–2; C) PgY1–3.
Intracellular concentration of DNr
The intracellular concentration of DNR in K562/A02 cells 
was explored by FCM assay after incubated for 48 hours. 
The mean fluorescence intensity of K562/A02 cells incubated 
with 0 µg/mL DNR was 170 ± 12; with DNR, 2490 ± 19; with 
MNP (Fe3O4) and DNR, 3318 ± 22; with PGY1–2 and DNR, 
5513 ± 20; and with combination of DNR, MNP (Fe3O4) 
and PGY1–2, 6930 ± 12, implicating that MNP (Fe3O4) and 
PGY1–2 with DNR together increased the intracellular DNR 
in K562/AO2 cells more effectively than that of MNP (Fe3O4) 
or PGY1–2 with DNR respectively (Figure 7).
Discussion
It is generally accepted that any access which could increase 
the effective concentration of intracellular chemotherapeutic 
agent was available to enhance the agent therapy. P-gp, among 
other ATP-binding cassette transporters, has important clinical 
implications since it is responsible for excretion of drugs and 
exotoxins and for resistance to multiple chemotherapeutic 
agents.15 The over-expression of P-gp in human tumors appears 
either at the time of diagnosis or prognosis. Inhibition of the 
function or expression of P-gp may result in re-sensitization 
of tumor cells to treatment with antineoplastic.16
To increase the intracellular effective concentration of 
chemotherapeutic agent, drugs packaged by liposome or 
multimer have been developed recently, as one of the most 
commonly used magnetic nanoparticles, MNP (Fe3O4) are International Journal of Nanomedicine 2010:5
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Figure 5 effects of MNP (Fe3O4) and/or PgY1–2 on MDr1 mrNA in K562 cells 
and K562/A02 cells after treatment for 48 hours by Quantitative real-time PCr 
analysis.
Notes: 1. K562/A02-untreated; 2. K562/A02 treated with 1.0 µg/mL DNr; 3. K562/
A02 treated with 10 µg/mL MNP (Fe3O4); 4. K562/A02 treated with PgY1–2; 5. K562/ 
A02 treated with 10 µg/mL MNP(Fe3O4) and 1.0 µg/mL DNr; 6. K562/A02 treated 
with PgY1–2 and 1.0 µg/mL DNr; 7. K562/A02 treated with 10 µg/mL MNP (Fe3O4), 
PgY1–2 and 1.0 µg/mL DNr; 8. K562-untreated. ﹡P , 0.05, when compared to 
K562/A02 incubated with 1.0 µg/mL DNr; ﹡﹡P , 0.05, when compared to K562/
A02 incubated with 1.0 µg/mL DNr in the presence of PgY1–2 or MNP (Fe3O4).
Abbreviations: MNP (Fe3O4), magnetic nanoparticles of Fe3O4; DNr, daunorubicin.
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Figure 4 effects of shrNA expression vectors on MDr1 mrNA and its protein 
in K562/A02 cells after treatment for 48 hours. A) Transcription of MDr1 mrNA 
detected by quantitative real-time PCr described before; B) expression of P-gp 
determined by Western-blot analysis described before.
Notes: 1. Negative control (PgC silencer-U6-neo-gFP empty plasmid); 2. Positive 
control  (PgC  silencer-U6-neo-gFP  gAPDh  plasmid);  3.  PgY1–1;  4.  PgY1–2; 
5. PgY1–3. ﹡P , 0.05, when compared to positive control group; P , 0.05, the 
group of transfected cells with PgY1–2 was less than that of transfected cells with 
PgY1–1 or PgY1–3.
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that MNP (Fe3O4) and PGY1–2 with DNR together could 
increase the intracellular concentration of DNR in K562/
AO2 cells more effectively.
To further evaluate MNP (Fe3O4) and shRNAs on reversal 
of multidrug resistance cells, the shRNA expression vectors 
called PGY1–1, PGY1–2 and PGY1–3were designated and 
confirmed by sequencing. The introduction of short, double-
stranded RNA complexes by transfection have been found 
to be a very efficient way to knock down gene expression in 
mammalian cells.6 Recently, a number of studies have shown 
that shRNAs transcribed under the control of RNA polymerase 
III (Pol III) promoters effectively degrade mRNAs in culture 
cells. siRNA technology is an efficient tool for the specific 
knockdown of a given target mRNA. Up to now, mainly 
more easily gained than others and they may aggregate in 
water or tissue fluid spontaneously with good biocompat-
ibility and low toxicity.17 MNP (Fe3O4) are widely used for 
targeted-drug carriers with target-orientation and sustained-
release properties.18 Previous studies have demonstrated the 
synergistic effect of MNP (Fe3O4) with anticancer drug on 
the drug accumulation of leukemia K562 cells may help it 
to inhibit the relative drug resistance.2 Similar results were 
observed in our study, it showed that after incubation with 
different agents for 48 hours, fluorescence intensity of K562/
A02 was increased when compared to control group. Interest-
ingly, fluorescence intensity of K562/A02 treated with DNR, 
MNP (Fe3O4) and PGY1–2 was more intensified than that of 
MNP (Fe3O4) or PGY1–2 with DNR respectively, implicating 
Table  1  The  cytotoxicity  of  DNr,  MNP  (Fe3O4)  with  DNr, 
PgY1–2 with DNr, MNP (Fe3O4) and PgY1–2 with DNr on 
K562/A02 for 48 hours determined by MTT assay (mean ± sD)
Groups IC50 of DNR (μg/mL)
DNr 14.82 ± 0.96
10 µg/mL MNP (Fe3O4) + DNr  4.75 ± 0.59 (3.15)﹡
1.3 µg/mL PgY1–2 + DNr  1.08 ± 0.37 (13.7)﹡
10 µg/mL MNP (Fe3O4) +
1.3 µg/mL PgY1–2 + DNr  0.97 ± 0.41 (15.3)﹡
Notes: The values in parentheses were fold reversal (Fr) calculated as follows:   
Fr = IC50 DNr alone/IC50 DNr + agent. ﹡P , 0.05, compared with DNr group.
Abbreviations: DNr, daunorubicin; Fr, fold reversal; IC50, inhibitory concentration 
at 50%; MNP (Fe3O4), magnetic nanoparticles of Fe3O4;rate; sD, standard deviation.
MNP (Fe3O4) −−− +−+−+
PGY1-2 
DNR
−−− −+−++
β-actin
P-gp
−++ −−+++
1 2345678
K562 K562/A02
Figure 6 effects of MNP (Fe3O4) and/or PgY1–2 with DNr on P-gp in K562 cells 
and K562/A02 cells for 48 hours by Western-blot assay.
Notes:  1.  K562-untreated;  2.  K562/A02-untreated;  3.  K562/A02  treated  with 
1.0 µg/mL DNr; 4. K562/A02 treated with 10 µg/ml MNP (Fe3O4); 5. K562/A02 
treated with PgY1-2; 6. K562/A02 treated with 10 µg/ml MNP (Fe3O4) and 1.0 µg/ml 
DNr; 7. K562/A02 treated with PgY1–2 and 1.0 µg/ml DNr; 8. K562/A02 treated 
with 10 µg/ml MNP (Fe3O4), PgY1–2 and 1.0 µg/ml DNr.
Abbreviations: MNP (Fe3O4), magnetic nanoparticles of Fe3O4; DNr, daunorubicin.International Journal of Nanomedicine 2010:5
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transient settings have been available, which are of limited 
value if the target proteins display a long   half-life.19 This 
problem may be circumvented by the use of viral systems for 
the stable expression of siRNAs. However, their pathogenic-
ity, laborious production, and systemic instability limit their 
broad application,20 at present, a lot of research showed that 
the use of shRNAs, which expressed from stable integrated 
plasmids, can reduce MDR1 mRNA in K562/A02 cells.20 Our 
present toxicity results clearly indicated that the inhibitory 
activity of MNP (Fe3O4) and PGY1–2 was significantly greater 
than that of PGY1–2 or MNP (Fe3O4) alone at the same dose 
in the K562/A02 cells. The fold reversals were 15.3 of the 
synergia compared with the 3.15 of MNP (Fe3O4) and 13.7 
of PGY1–2 alone. Furthermore, the transcription of MDR1 
in K562/A02 cells preincubated with DNR in the absence or 
presence of MNP (Fe3O4) or vector PGY1–2 was higher when 
compared to parented sensitive K562 cells,   furthermore, DNR 
with MNP (Fe3O4) and PGY1–2 decreased the transcription 
of MDR1 mRNA in K562/A02 cells more effectively than 
with MNP (Fe3O4) or with PGY1–2 alone, suggesting that 
  combination of MNP (Fe3O4) and PGY1–2 has a potential 
benefit to down-regulate the transcription of MDR1 mRNA, 
we also found that MNP (Fe3O4) and PGY1–2 with DNR 
together decreased the expression of P-gp more effectively 
than MNP (Fe3O4) or PGY1–2 with DNR alone (P , 0.05), 
suggesting that a combination of MNP (Fe3O4) and PGY1–2 
also has a potential benefit to down-regulate the expression 
of P-gp. Interestingly, the expression levels of P-gp were in 
accordance with the transcription MDR1 levels of mRNA. 
Therefore, MNP (Fe3O4) and PGY1–2 could synergistically 
reverse MDR. To obtain more data supporting this theory, 
further in vitro and in vivo studies are required.
Conclusion
Our study demonstrates for the first time that MNP (Fe3O4) 
and shRNA expression vector significantly reversed MDR, 
and the distinct synergistic effect of which owes to the down-
regulation of expression of mdr1 gene, suggesting that a 
combination of MNP (Fe3O4) and shRNA expression vector 
may be a more sufficient and less toxic anti-MDR method.
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